1-cyclopropyl-1-[4-(trifluoromethyl)phenyl]methanamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-cyclopropyl-1-[4-(trifluoromethyl)phenyl]methanamine
• 英文别名: Cyclopropyl(4-(trifluoromethyl)phenyl)methanamine；cyclopropyl-[4-(trifluoromethyl)phenyl]methanamine
• 化学式: C₁₁H₁₂F₃N
• 分子量: 215.218
• InChiKey: ZQGDJHVPZJFVNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-甲氧基-N-甲基-4-(三氟甲基)苯甲酰胺 在 palladium on activated charcoal 吡啶 、 氨 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 17.0h， 生成 1-cyclopropyl-1-[4-(trifluoromethyl)phenyl]methanamine
  参考文献：
  名称：

  α-Methylation at benzylic fragment of N-aryl-N′-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model

  摘要：

  SAR studies for N-aryl-N '-benzyl urea class of TRPV1 antagonists have been extended to cover alpha-benzyl alkylation. Alkylated compounds showed weaker in vitro potencies in blocking capsaicin activation of TRPV1 receptor, but possessed improved pharmacokinetic properties. Further structural manipulations that included replacement of isoquinoline core with indazole and isolation of single enantiomer led to TRPV1 antagonists like (R)-16a with superior pharmacokinetic properties and greater potency in animal model of inflammatory pain. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.105

文献信息

• Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
  申请人：——

  公开号：US20040157849A1

  公开（公告）日：2004-08-12

  Compounds of formula (I) 1 are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

  式（I）的化合物是新颖的VR1拮抗剂，可用于治疗疼痛、炎症性热性过敏、尿失禁和膀胱过度活动。
• BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF
  申请人：AMGEN INC.

  公开号：US20190077793A1

  公开（公告）日：2019-03-14

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

  本发明提供了一种式（I）的化合物或其药学上可接受的盐，包括本发明化合物的药物组合物，制造本发明化合物的方法以及它们的治疗用途。
• Rapid, one-pot synthesis of α,α-disubstituted primary amines by the addition of Grignard reagents to nitriles under microwave heating conditions
  作者：Brian T. Gregg、Kathryn C. Golden、John F. Quinn、Hong-Jun Wang、Wei Zhang、Ruifang Wang、Francis Wekesa、Dmytro O. Tymoshenko

  DOI：10.1016/j.tetlet.2009.04.081

  日期：2009.7

  A series of α,α-disubstituted amines have been prepared in a simple and efficient one-pot procedure by the addition of Grignard reagents to a series of aliphatic, aromatic, and heteroaromatic nitriles. Key to this reported procedure is the unprecedented addition of the Grignard reagent to the nitrile under heating by microwave irradiation which both significantly improves reaction yields and reduces

  通过将格氏试剂添加到一系列脂族，芳族和杂芳族腈中，以简单有效的一锅法制备了一系列α，α-二取代胺。该报道方法的关键是在微波辐射加热下，将格氏试剂前所未有地添加到腈中，这既显着提高了反应产率，又缩短了反应时间。通常，格利雅（Grignard）加成反应在100°C下5-10分钟内完成，然后用硼氢化钠快速还原，得到目标胺。
• [EN] FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR<br/>[FR] COMPOSES AZABICYCLIQUES FUSIONNES QUI INHIBENT LE RECEPTEUR (VR1) SOUS-TYPE 1 DU RECEPTEUR VANILLOIDE
  申请人：ABBOTT LAB

  公开号：WO2003070247A1

  公开（公告）日：2003-08-28

  Compounds of formula (I), are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

  化学式为(I)的化合物是新颖的VR1拮抗剂，可用于治疗疼痛、炎症性热性过敏、尿失禁和膀胱过度活动。
• Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor
  申请人：——

  公开号：US20040209884A1

  公开（公告）日：2004-10-21

  Compounds of formula (I) 1 are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

  式(I)1的化合物是一种新型的VR1拮抗剂，可用于治疗疼痛、炎性热性过敏、尿失禁和膀胱过度活动。